person

Celina A.

Country
Portugal
Department
PT30001:Hematologia

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
72
Sites with multiple studies

Has run more than one trial at 72 of 282 partner sites.

Specializations

Hematologic Disorders

The investigator specializes in treating myelofibrosis, focusing particularly on advanced disease states including intermediate-2 and high-risk cases. Their research interests center on innovative therapeutic approaches for patients who have shown resistance to conventional treatments.

  • Advanced Myelofibrosis Management
  • Treatment-Resistant Blood Disorders
  • Survival Outcome Studies

The investigator evaluates novel therapeutic agents against established treatment protocols for hematologic conditions.

Treatment Innovation

Their research encompasses the evaluation of telomerase inhibitor therapies and their potential in treating resistant forms of myelofibrosis. The investigator's work involves comparing emerging therapeutic options with current standard treatments.

  • Novel Therapeutic Approaches
  • Alternative Treatment Strategies
  • Comparative Treatment Studies

The investigator focuses on developing treatment options for patients who have exhausted standard therapeutic approaches.

Clinical Outcomes

The investigator specializes in assessing overall survival outcomes in hematologic malignancies. Their work involves evaluating treatment efficacy in patients with advanced myelofibrosis who have shown resistance to JAK-inhibitor treatments.

  • Survival Analysis
  • Treatment Response Assessment
  • Drug Resistance Studies

Their research aims to improve treatment outcomes for patients with resistant forms of myelofibrosis.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.